| Literature DB >> 27077923 |
Jisu Hu1,2, Wenbo Wu3, Bin Zhu3, Huiting Wang3, Renyuan Liu3, Xin Zhang3, Ming Li3, Yongbo Yang4, Jing Yan5, Fengnan Niu6, Chuanshuai Tian3, Kun Wang3, Haiping Yu3, Weibo Chen7, Suiren Wan1, Yu Sun1, Bing Zhang3.
Abstract
Many modalities of magnetic resonance imaging (MRI) have been confirmed to be of great diagnostic value in glioma grading. Contrast enhanced T1-weighted imaging allows the recognition of blood-brain barrier breakdown. Perfusion weighted imaging and MR spectroscopic imaging enable the quantitative measurement of perfusion parameters and metabolic alterations respectively. These modalities can potentially improve the grading process in glioma if combined properly. In this study, Bayesian Network, which is a powerful and flexible method for probabilistic analysis under uncertainty, is used to combine features extracted from contrast enhanced T1-weighted imaging, perfusion weighted imaging and MR spectroscopic imaging. The networks were constructed using K2 algorithm along with manual determination and distribution parameters learned using maximum likelihood estimation. The grading performance was evaluated in a leave-one-out analysis, achieving an overall grading accuracy of 92.86% and an area under the curve of 0.9577 in the receiver operating characteristic analysis given all available features observed in the total 56 patients. Results and discussions show that Bayesian Network is promising in combining features from multiple modalities of MRI for improved grading performance.Entities:
Mesh:
Year: 2016 PMID: 27077923 PMCID: PMC4831834 DOI: 10.1371/journal.pone.0153369
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Examples of different enhancement extent.
The left column is a case of glioblastoma with apparent enhancement, the middle a case of high-grade glioma with slight enhancement (white arrow) and the right a low-grade glioma with negative enhancement. Upper row axial T2-weighted images. Lower row axial T1W+C images.
Fig 2The pseudo-color maps of metabolite ratios in MRSI.
(A) Cho/Cr map. (B) NAA/Cr. (C) Lac/Cr map/ (D) Lip13/Cr map. (E) The VOI boundary (green) and the manually selected region (red).
Statistical analysis results of the features.
| Features | High grade | Low grade | P value |
|---|---|---|---|
| Mean + SD | Mean + SD | ||
| T1W+C | <0.0001 | ||
| nrCBV | 3.762 + 2.234 | 1.482 + 0.624 | <0.0001 |
| nMTT | 1.483 + 0.779 | 1.007 + 0.115 | 0.0007 |
| nrCBF | 2.653 + 1.514 | 1.571 + 0.895 | 0.0003 |
| nT0 | 1.048 + 0.212 | 1.030 + 0.120 | 0.9773 |
| nTTP | 1.088 + 0.168 | 1.007 + 0.051 | 0.0014 |
| Cho/Cr | 1.169 + 0.522 | 0.565 + 0.179 | 0.0005 |
| NAA/Cr | 0.357 + 0.186 | 0.680 + 0.340 | 0.0044 |
| Lac/Cr | 109.598 + 206.765 | 1.462 + 2.919 | 0.0001 |
| Lip13/Cr | 37.762 + 34.745 | 1.795 + 2.680 | <0.0001 |
SD, standard deviation; T1W+C, contrast enhanced T1-weighted imaging; nrCBV, normalized regional cerebral blood volume; nMTT, normalized mean transit time; nrCBF, normalized regional cerebral blood flow; nT0, normalized T0; nTTP, normalized time to peak; Cho, choline; NAA, N-acetyl aspartate; Lac, lactate; Lip13, lipid at 1.3 ppm; Cr, creatine.
Grading accuracies of the BNs with perfusion features.
| Features used | Grading accuracy |
|---|---|
| nrCBV nMTT nrCBF nTTP | 0.8431 |
| nrCBV nMTT nrCBF | 0.8431 |
| nrCBV nrCBF nTTP | 0.8235 |
| nrCBV nrCBF | 0.8235 |
| nrCBV nTTP | 0.8039 |
| nrCBV | 0.8039 |
| nrCBV nMTT nTTP | 0.7843 |
| nrCBV nMTT | 0.7843 |
| nMTT nrCBF nTTP | 0.7059 |
| nMTT nrCBF | 0.7059 |
| nrCBF nTTP | 0.6863 |
| nrCBF | 0.6863 |
| nMTT nTTP | 0.6471 |
| nMTT | 0.6471 |
| nTTP | 0.6275 |
nrCBV, normalized regional cerebral blood volume; nMTT, normalized mean transit time; nrCBF, normalized regional cerebral blood flow; nT0, normalized T0; nTTP, normalized time to peak.
Fig 3Some BNs constructed in this study.
(A) The BN of perfusion features with nTTP. (B) The BN of perfusion features without nTTP. (C) The BN of T1W+C and perfusion features. (D) The BN of MRSI features with Lac/Cr. (E) The BN of MRSI features without Lac/Cr. (F) The final BN structure.
Grading accuracies of the BNs with T1W+C and perfusion features.
| Features used | Grading accuracy |
|---|---|
| T1W+C nrCBV nMTT nrCBF | 0.9020 |
| T1W+C nrCBV nMTT | 0.8431 |
| T1W+C nrCBV nrCBF | 0.8431 |
| T1W+C nMTT nrCBF | 0.8431 |
| T1W+C nrCBV | 0.8431 |
| T1W+C nMTT | 0.8431 |
| T1W+C nrCBF | 0.8431 |
| T1W+C | 0.8431 |
T1W+C, contrast enhanced T1-weighted imaging; nrCBV, normalized regional cerebral blood volume; nMTT, normalized mean transit time; nrCBF, normalized regional cerebral blood flow.
Grading accuracies of the BNs with MRSI features.
| Features used | Grading accuracy |
|---|---|
| Cho/Cr NAA/Cr Lip13/Cr | 0.8846 |
| Cho/Cr Lip13/Cr | 0.8846 |
| NAA/Cr Lip13/Cr | 0.8846 |
| Lip13/Cr | 0.8846 |
| Cho/Cr NAA/Cr Lac/Cr Lip13/Cr | 0.8462 |
| Cho/Cr Lac/Cr Lip13/Cr | 0.8462 |
| NAA/Cr Lac/Cr Lip13/Cr | 0.8462 |
| Lac/Cr Lip13/Cr | 0.8462 |
| Cho/Cr NAA/Cr Lac/Cr | 0.8077 |
| Cho/Cr NAA/Cr | 0.8077 |
| Cho/Cr Lac/Cr | 0.8077 |
| Cho/Cr | 0.8077 |
| NAA/Cr Lac/Cr | 0.7692 |
| NAA/Cr | 0.7692 |
| Lac/Cr | 0.7692 |
Cho, choline; NAA, N-acetyl aspartate; Lac, lactate; Lip13, lipid at 1.3 ppm; Cr, creatine.
Grading accuracies of the final BN with different observations of the features.
| Number of test cases | Observed features | Grading accuracy | Number of wrong predictions | AUC |
|---|---|---|---|---|
| 56 | T1W+C | 0.8571 | 8 | 0.8154 |
| T1W+C perfusion | 0.9017 | 5 | 0.9038 | |
| T1W+C MRSI | 0.8929 | 6 | 0.9205 | |
| T1W+C perfusion MRSI | 0.9286 | 4 | 0.9577 | |
| 51 | Perfusion | 0.8824 | 6 | 0.8494 |
| Perfusion T1W+C | 0.9020 | 5 | 0.9037 | |
| Perfusion MRSI | 0.8824 | 6 | 0.9099 | |
| Perfusion T1W+C MRSI | 0.9216 | 4 | 0.9519 | |
| 26 | MRSI | 0.8846 | 3 | 0.9625 |
| MRSI T1W+C | 0.9615 | 1 | 0.9688 | |
| MRSI perfusion | 0.9615 | 1 | 1 | |
| MRSI T1W+C perfusion | 1 | 0 | 1 |
T1W+C, contrast enhanced T1-weighted imaging; MRSI, MR spectroscopic imaging; AUC, area under the curve.
Fig 4The ROC curves in the three datasets.
(A) The ROC curve in the 56 cases. (B) The ROC curve in the 51 cases. (C) The ROC curve in the 26 cases.